Clinically meaningful treatment goals were defined as an FPG of ≤7.2 mmol/dL, a decline in HbA1c to ≤7%, or a decrease of ≥0.5% in HbA1c. Using systematic search criteria, 20 randomized controlled trials of chromium supplementation in T2DM patients were identified. This narrative review examines the efficacy of chromium supplements for improving glycemic control as measured by decreases in fasting plasma glucose (FPG) or hemoglobin A1c (HbA1c). Some adults with type 2 diabetes mellitus (T2DM) believe that chromium-containing supplements will help control their disease, but the evidence is mixed. Bailey is with the Department of Nutrition Science, Purdue University, West Lafayette, Indiana, USA.
Dwyer is with the School of Medicine and Friedman School of Nutrition Science and Policy, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts, USA. Bailey are with the Office of Dietary Supplements, National Institutes of Health, Bethesda, Maryland, USA.
0 kommentar(er)
